DEFYMED
Defymed is a worldwide leader in the development of innovative implantable medical devices that change the paradigm of therapeutics' administration. Defymed's innovations were developed to limit adverse events related to current standard of care based on site specific delivery of therapeutics. Our solutions aim for a precise administration of drugs, in a physiologic site, in order to improve disease's management and patients' quality of life. Up to date, two first in class technologies were dev... eloped by Defymed: MailPan®, a physiologic cell encapsulation device, and ExOlin®, a targeted drug delivery device. Defymed owns an exclusive technology and know-how which positions its medical devices as a platform to meet several therapeutic applications, among which type 1 diabetes, hemophilia and cancer management. Defymed is certified ISO13485:2016. Defymed relies also on a strong and unique worldwide network gathering experts from the cell therapy and drug delivery fields. Defymed has been rewarded several times in Europe and in the USA, for its unique approaches to reinvent patients' journey.
DEFYMED
Industry:
Diabetes Health Care Medical Device
Founded:
2011-03-07
Address:
Strasbourg, Alsace, France
Country:
France
Website Url:
http://www.defymed.com
Total Employee:
11+
Status:
Active
Contact:
+33390410446
Email Addresses:
[email protected]
Total Funding:
5.47 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Content Delivery Network Mobile Non Scaleable Content
Similar Organizations
Blackfynn
Blackfynn is a technology-driven, life-sciences company dedicated to transforming the way neurological diseases are diagnosed and treated.
CeQur
CeQur develops and commercializes insulin delivery systems, giving people with type 2 diabetes freedom from multiple daily injections.
Sensome
Sensome offers micro-sensor technology to turn medical devices into connected healthcare devices.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Current Advisors List
Current Employees Featured
Founder
Investors List
Cap Innov'Est
Cap Innov'Est investment in Seed Round - Defymed
Cap Innov'Est
Cap Innov'Est investment in Seed Round - Defymed
Emertec
Emertec investment in Seed Round - Defymed
CeeD (Centre Européen d'étude du diabète)
CeeD (Centre Européen d'étude du diabète) investment in Seed Round - Defymed
CTTM
CTTM investment in Seed Round - Defymed
CeeD (Centre Européen d'étude du diabète)
CeeD (Centre Européen d'étude du diabète) investment in Seed Round - Defymed
Emertec
Emertec investment in Seed Round - Defymed
CeeD (Centre Européen d'étude du diabète)
CeeD (Centre Européen d'étude du diabète) investment in Seed Round - Defymed
CTTM
CTTM investment in Seed Round - Defymed
Statice
Statice investment in Seed Round - Defymed
Official Site Inspections
http://www.defymed.com
- Host name: 4-95-162-69.static.reverse.lstn.net
- IP address: 69.162.95.4
- Location: Dallas United States
- Latitude: 32.7767
- Longitude: -96.805
- Metro Code: 623
- Timezone: America/Chicago
- Postal: 75202
More informations about "Defymed"
Defymed - Crunchbase Company Profile & Funding
Defymed is certified ISO13485:2016. Defymed relies also on a strong and unique worldwide network gathering experts from the cell therapy and drug delivery fields. Defymed has been rewarded several times in Europe and in the USA, …See details»
Defymed - Org Chart, Teams, Culture & Jobs - The Org
Defymed is a worldwide leader in the development of innovative implantable medical devices that change the paradigm of therapeutics' administration. Defymed's innovations were developed …See details»
defymed.com
We would like to show you a description here but the site won’t allow us.See details»
Defymed - LinkedIn
Defymed | 4,613 followers on LinkedIn. Advanced therapies inspired for you | Defymed is a French SME that develops innovative medical devices aimed at treating patients …See details»
Severine SIGRIST - President, CEO at Defymed - The Org
In addition to their role at Defymed, Sigrist has held various positions at the Centre européen d'étude du Diabète (CeeD). Severine started as a postdoctoral researcher in 2000 and eventually became the Director of the laboratory in …See details»
Defymed Company Profile 2024: Valuation, Funding
Defymed has 17 total employees. What industry is Defymed in? Defymed’s primary industry is Therapeutic Devices. Is Defymed a private or public company? Defymed is a Private company. What is Defymed’s current revenue? The …See details»
Defymed - Products, Competitors, Financials, Employees, …
Defymed is initially focused on an application for the treatment of type 1 diabetes. The first product developed is MailPan®, an implantable bio-artificial pancreas designed to restore …See details»
Defymed - Company Profile - Tracxn
Nov 21, 2024 Defymed ranks 4th among 6 active competitors. 5 of its competitors are funded while 1 has exited. Overall, Defymed and its competitors have raised over $290M in funding …See details»
Defymed - CoBee Company Profile & Funding Rounds
Defymed is a worldwide leader in the development of innovative implantable medical devices that change the paradigm of therapeutics&s; administration. Defymed&s;s innovations were …See details»
Defymed - Crunchbase
Defymed is a leader in the development of innovative implantable medical devices that change the paradigm of therapeutics' administration. ... Products. Resources. Pricing. Resources. Log …See details»
Defymed | Insights
Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
Defymed - Contacts, Employees, Board Members, Advisors & Alumni
Defymed has 5 current employee profiles, including Chief Operating Officer Richard Bouaoun. Defymed has 6 board members and advisors, including Pascal Neuville . ContactsSee details»
Defymed | Strasbourg, Alsace, France Startup - Gust
Defymed® develops an implantable bio-artificial pancreas, named MAILPAN (MAcro-encapsulation of PANcreatic Islets) to treat type 1 diabetic patients. In the future other …See details»
DOSSIER DE PRESSE - defymed.com
Lancement de la Start-Up DEFYMED pour le développement d’un pancréas bioartificiel. Une initiative du Centre européen d’étude du Diabète. La Start-Up DEFYMED, dont l’objet est de …See details»
Defymed receives approval to start its pilot clinical study
Jan 25, 2022 Defymed is now interested in using its know-how to improve the treatment of other diseases such as cancer or haemophilia. ... Organization Profile. Defymed. Contact Cision. …See details»
Defymed - Updates, News, Events, Signals & Triggers - Crunchbase
Defymed is a leader in the development of innovative implantable medical devices that change the paradigm of therapeutics' administration. Search Crunchbase. Start Free Trial . Chrome …See details»
Defymed Accelerates Its Development in the United States: One …
Sep 20, 2019 DEFYMED Manuel Pires, Business Developer +33 (0)3 90 41 04 46 - [email protected] OXYGEN | Press contact Elise Cordier +33 (0)3 67 22 03 25 - …See details»
Defymed - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
Defymed | Strasbourg - Facebook
Defymed, Strasbourg, France. 449 likes. Defymed develops and markets implantable medical devices for diverse therapeutic applications.See details»
Defymed - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Jul 15, 2024 The intellectual property of Defymed includes 13 registered patents primarily in the ' Medical Or Veterinary Science; Hygiene ' category, according to IPqwery. Additionally, …See details»